title: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
abstract: In 1996 the American Society for Therapeutic Radiology and Oncology (ASTRO) sponsored a Consensus Conference to establish a definition of biochemical failure after external beam radiotherapy (EBRT). The ASTRO definition defined prostate specific antigen (PSA) failure as occurring after three consecutive PSA rises after a nadir with the date of failure as the point halfway between the nadir date and the first rise or any rise great enough to provoke initiation of therapy. This definition was not linked to clinical progression or survival; it performed poorly in patients undergoing hormonal therapy (HT), and backdating biased the Kaplan-Meier estimates of event-free survival. A second Consensus Conference was sponsored by ASTRO and the Radiation Therapy Oncology Group in Phoenix, Arizona, on January 21, 2005, to revise the ASTRO definition. The panel recommended: (1) a rise by 2 ng/mL or more above the nadir PSA be considered the standard definition for biochemical failure after EBRT with or without HT; (2) the date of failure be determined "at call" (not backdated). They recommended that investigators be allowed to use the ASTRO Consensus Definition after EBRT alone (no hormonal therapy) with strict adherence to guidelines as to "adequate follow-up." To avoid the artifacts resulting from short follow-up, the reported date of control should be listed as 2 years short of the median follow-up. For example, if the median follow-up is 5 years, control rates at 3 years should be cited. Retaining a strict version of the ASTRO definition would allow comparisons with a large existing body of literature.
authors.affiliation: Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143-1708, and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. roach@radonc17.ucsf.edu
authors.forename: Mack
authors.initials: M
authors.lastname: Roach
authors.forename: Gerald
authors.initials: G
authors.lastname: Hanks
authors.forename: Howard
authors.initials: H
authors.lastname: Thames
authors.forename: Paul
authors.initials: P
authors.lastname: Schellhammer
authors.forename: William U
authors.initials: WU
authors.lastname: Shipley
authors.forename: Gerald H
authors.initials: GH
authors.lastname: Sokol
authors.forename: Howard
authors.initials: H
authors.lastname: Sandler
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy; D012016:Reference Values; D012680:Sensitivity and Specificity; D012955:Societies, Medical; D017211:Treatment Failure
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen